Rouanne, Mathieu

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer

Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., et al. (2019) · Journal of Clinical Investigation

PARP inhibition in cancer therapyinterferon and immune responses

Cited by 332

Probiotic-guided CAR-T cells for solid tumor targeting

Vincent, R. L., Gurbatri, C. R., Li, F., Vardoshvili, A., Coker, C., Im, J., Ballister, E. R., Rouanne, M., Savage, T., de los Santos-Alexis, K., et al. (2023) · Science

Bacterial Cancer TherapyCAR-T cell therapy research

Cited by 273

Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis

Savage, T. M., Fortson, K. T., de los Santos-Alexis, K., Oliveras-Alsina, A., Rouanne, M., Rae, S. S., Gamarra, J. R., Shayya, H., Kornberg, A., Cavero, R., et al. (2024) · Immunity

Liver physiology and pathologyLiver Disease Diagnosis and Treatment

Cited by 120

Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

Goubet, A.-G., Lordello, L., Alves Costa Silva, C., Peguillet, I., Gazzano, M., Mbogning-Fonkou, M. D., Thelemaque, C., Lebacle, C., Thibault, C., Audenet, F., et al. (2022) · Cancer Discovery

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 86

From mucosal infection to successful cancer immunotherapy

Goubet, A.-G., Rouanne, M., Derosa, L., Kroemer, G., & Zitvogel, L. (2023) · Nature Reviews Urology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 11